CUE BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.63 USD | +2.52% |
|
+0.31% | -38.26% |
| May. 09 | Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 365 | 378.8 | 359.2 | 122.7 | 119.1 | 79.29 | - | - |
| Enterprise Value (EV) 1 | 365 | 293.9 | 294.8 | 122.7 | 119.1 | 79.29 | 79.29 | 79.29 |
| P/E ratio | -9.56 x | -8.02 x | -8.02 x | -1.91 x | -2.38 x | -1.63 x | -1.62 x | -1.55 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 106 x | 120 x | 24 x | 98.5 x | 21.7 x | 7.52 x | 5.4 x | 4.08 x |
| EV / Revenue | 106 x | 120 x | 24 x | 98.5 x | 21.7 x | 7.52 x | 5.4 x | 4.08 x |
| EV / EBITDA | - | -8,611,598 x | -8,461,223 x | - | - | - | - | - |
| EV / FCF | - | -11,447,277 x | -9,036,839 x | - | - | - | - | - |
| FCF Yield | - | -0% | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 22,994 | 30,278 | 31,761 | 43,043 | 45,123 | 48,643 | - | - |
| Reference price 2 | 15.88 | 12.51 | 11.31 | 2.850 | 2.640 | 1.630 | 1.630 | 1.630 |
| Announcement Date | 3/12/20 | 3/9/21 | 3/16/22 | 3/21/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.458 | 3.154 | 14.94 | 1.245 | 5.49 | 10.54 | 14.69 | 19.45 |
| EBITDA | - | -43.99 | -42.45 | - | - | - | - | - |
| EBIT 1 | -36.77 | -45.04 | -43.71 | -53.22 | -52.15 | -52.64 | -63.87 | -71.21 |
| Operating Margin | -1,063.21% | -1,427.96% | -292.56% | -4,274.3% | -949.89% | -499.37% | -434.71% | -366.09% |
| Earnings before Tax (EBT) 1 | -36.29 | -44.58 | -43.67 | -53.01 | -50.73 | -51.75 | -62.74 | -69.98 |
| Net income 1 | -36.7 | -44.78 | -44.16 | -53.01 | -50.73 | -51.75 | -62.74 | -69.98 |
| Net margin | -1,061.18% | -1,419.79% | -295.56% | -4,257.08% | -924.1% | -490.91% | -427.03% | -359.72% |
| EPS 2 | -1.660 | -1.560 | -1.410 | -1.490 | -1.110 | -1.000 | -1.004 | -1.053 |
| Free Cash Flow | - | -33.09 | -39.75 | - | - | - | - | - |
| FCF margin | - | -1,049.01% | -266.04% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/9/21 | 3/16/22 | 3/21/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.254 | 1 | 0.026 | 0.068 | 0.1512 | 0.187 | 1.382 | 2.1 | 1.821 | 1.717 | 1.289 | 1.293 | 6.248 | 1.402 | 1.446 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.893 | -14.24 | -13.09 | -11.03 | -14.87 | -13.38 | -13.52 | -11.42 | -13.83 | -12.67 | -13.73 | -15.07 | -11.17 | -17.81 | -18.82 |
| Operating Margin | -95.62% | -1,423.8% | -50,346.15% | -16,222.06% | -9,829.93% | -7,155.08% | -978.08% | -543.76% | -759.58% | -737.8% | -1,064.86% | -1,165.52% | -178.86% | -1,270.57% | -1,301.04% |
| Earnings before Tax (EBT) 1 | -7.889 | -14.26 | -13.21 | -10.96 | -14.59 | -13.11 | -13.18 | -11 | -13.43 | -12.35 | -13.58 | -14.84 | -11 | -17.83 | -18.87 |
| Net income 1 | -8.384 | -14.26 | -13.21 | -10.96 | -14.59 | -13.11 | -13.18 | -11 | -13.43 | -12.35 | -13.58 | -14.84 | -11 | -17.83 | -18.87 |
| Net margin | -101.57% | -1,425.5% | -50,800% | -16,110.29% | -9,649.13% | -7,010.16% | -954.05% | -524.05% | -737.73% | -719.1% | -1,053.41% | -1,147.73% | -176.07% | -1,272.35% | -1,304.49% |
| EPS 2 | -0.2500 | -0.4400 | -0.3700 | -0.3100 | -0.3800 | -0.2900 | -0.2900 | -0.2400 | -0.2900 | -0.2500 | -0.2725 | -0.2575 | -0.2075 | -0.3500 | -0.3550 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/22 | 5/10/22 | 8/4/22 | 11/14/22 | 3/21/23 | 5/9/23 | 8/8/23 | 11/3/23 | 3/28/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 84.9 | 64.4 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -33.1 | -39.8 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.05 | - | 0.91 | - | - | 1.34 | 1.79 | 2.22 |
| Capex / Sales | 1.34% | - | 6.11% | - | - | 12.7% | 12.2% | 11.4% |
| Announcement Date | 3/12/20 | 3/9/21 | 3/16/22 | 3/21/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.63
USD
Average target price
9.4
USD
Spread / Average Target
+476.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.26% | 79.29M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- CUE Stock
- Financials Cue Biopharma, Inc.
